Han Biomedical

Han Biomedical CROIC

The Cash Return on Invested Capital (CROIC) of Han Biomedical (6999.TWO) as of Oct 29, 2026 is 12.11 %. In the previous year, Cash Return on Invested Capital (CROIC) was 14.46 % — a change of -16.29% (lower).

CROIC

12.11 %

YoY

-16.29%

Last updated:

Cash Return on Invested Capital (CROIC) of Han Biomedical is 2024 12.11 % . Cash Return on Invested Capital (CROIC) of Han Biomedical was 2023 14.46 % . It decreases by -16.29% lower compared to the previous year.

The Han Biomedical CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2022
11.77 TWD
Jan 1, 2023
14.46 TWD
Jan 1, 2024
12.11 TWD
The Han Biomedical CROIC history
YEARCROICYoY
12.11 %-16.29%
14.46 %+22.94%
11.77 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Han Biomedical Stock analysis

What does Han Biomedical do? Han Biomedical Inc generates revenue through the design, development, and production of medical materials for tissue reconstruction and repair. Its primary products are BarriGel, a post-surgical anti-adhesion solution that prevents complications by extending degradation time, and Hancare, a collagen scaffolding material made from medical-grade collagen that adheres to wounds and absorbs exudate. The company distributes these products mainly within Taiwan's domestic market, targeting healthcare providers and medical facilities that require advanced tissue repair solutions. The firm focuses on natural biomedical materials, emphasizing product innovation for post-surgical care. BarriGel and Hancare are positioned as specialized medical solutions for wound management and adhesion prevention, catering to hospitals and clinics seeking effective tissue repair technologies. Revenue streams are derived from direct sales of these branded products to domestic healthcare institutions without external distribution channels. Han Biomedical Inc's business model centers on proprietary medical materials developed for specific clinical applications. The company's product portfolio includes BarriGel and Hancare, both designed to address post-surgical challenges with natural materials. Domestic market distribution ensures consistent revenue from local healthcare providers who prioritize advanced tissue repair solutions. Han Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Han Biomedical stock

Cash Return on Invested Capital (CROIC) of Han Biomedical is 12.11 % in 2024.

Cash Return on Invested Capital (CROIC) of Han Biomedical changed from 14.46 % to 12.11 %, representing a -16.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Han Biomedical since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Han Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Han Biomedical

All Key Metrics — Han Biomedical